NCT00591734已完成2 期
A Phase II Trial of RAD001 Plus Bevacizumab in the Treatment of Patients With Metastatic Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 15
- 主要终点
- Progression-free Survival
研究概览
简要总结
This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.
详细描述
All patients will begin treatment with the same doses of RAD001 and bevacizumab. Patients will receive 6 weeks of treatment, followed by re evaluation. Patients with objective response or stable disease will continue treatment until disease progression.
During the study, all patients will receive 10 mg of RAD001 orally daily and 15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
Fifty-five patients will be enrolled in this multi-centered study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed melanoma.
- •Unresectable stage IV disease, or recurrent disease with metastases.
- •Measurable disease (by Response Evaluation Criteria in Solid Tumors [RECIST]) or measurable skin lesions.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or
- •Life expectancy >=12 weeks.
- •Patients are allowed 0-2 prior treatment regimens containing chemotherapy and/or immunotherapy (interferon, interleukin 2).
- •Women of childbearing potential must have a negative serum pregnancy test with 7 days before beginning treatment.
- •Absolute neutrophil count (ANC) >=1500/µL, and platelets >=100,000/µL.
- •Serum creatinine <=2.0 mg/dL.
- •Serum bilirubin <=1.5 mg/dL institutional upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 × ULN or <5 × ULN in patients with documented liver metastases.
排除标准
- •Previous treatment with bevacizumab or other anti-angiogenesis agents.
- •Previous treatment with mTOR inhibitors.
- •Drugs or substances known to be inhibitors or inducers of the isoenzyme CYP3A are not allowed.
- •Treatment with investigational agents within 4 weeks of study entry.
- •Treatment with more than two previous chemotherapy regimens.
- •Immunization with attenuated live vaccines within one week of study or anytime during study treatment period.
- •Female patients who are pregnant or breastfeeding.
- •Central nervous system (CNS) involvement by metastatic melanoma.
- •CNS disease (e.g., seizures not controlled with standard medical therapy, history of stroke).
- •Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:
- •Severely impaired lung function.
- •Uncontrolled diabetes as defined by fasting serum glucose >1.5 ULN,
- •Any acute or chronic uncontrolled infection/disorder.
- •Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.
- •Any acute or chronic uncontrolled infection/disorder.
- •Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.
- •Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
- •Acute myocardial infarction (MI) with the previous 6 months.
- •Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, New York Heart Association [NYHA] Class II or greater congestive heart failure [CHF], serious cardiac arrhythmia requiring medication), or >= grade 2 vascular disease.
- •Clinical history of hemoptysis or hematemesis.
- •Clinical evidence or history of a bleeding diathesis or coagulopathy.
- •Major surgical procedures, fine-needle aspirations, or core biopsies with 7 days of starting treatment.
- •Patients with PEG tubes or G-tubes.
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- •Proteinuria at screening as demonstrated by either
- •Urine protein:creatinine (UPC) ratio >= 1.0 at screening OR
- •Urine dipstick for proteinuria >= 2+ (patients discovered to have >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate <= 1g of protein in 24 hours to be eligible).
研究组 & 干预措施
Intervention
Experimental
All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
干预措施: Bevacizumab (Drug)
Intervention
Experimental
All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
干预措施: Everolimus (Drug)
结局指标
主要结局
Progression-free Survival
时间窗: 13 months
Length of time, in months, that patients were alive from their first date of protocol treatment until worsening of their disease
次要结局
- Overall Survival Rate(1 year)
- Objective Response Rate (ORR)(13 months)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT00886691GOG Foundation150
招募中
2 期
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerSolid TumorsAdvanced Solid TumorsMetastatic CancerNCT05904457Asan Medical Center32
已完成
2 期
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma MultiformeGlioblastoma MultiformeNCT01115491Hoffmann-La Roche32
撤回
2 期
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth SyndromeSegmental Overgrowth SyndromeNCT02569125Jochen Roessler
已完成
2 期
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCarcinomaAdenocarcinomaRenal CellNephroid CarcinomaHypernephroidNCT00719264Novartis Pharmaceuticals365